Fig 3.

Immunohistochemistry results for antigen expression (column A, IL13Rα2; column B, EphA2; column C, survivin) in patients 11 (postmortem specimen) and 13 (pretreatment specimen), illustrating the range of antigen expression observed. Patient 11 had diffuse immunoreactivity for all three antigens, whereas patient 13 had absent expression of EphA2 and low-level expression of survivin in a minority of cells. High levels of expression of interleukin 13 receptor alpha 2 were observed, which was one antigen to which the patient mounted a strong enzyme-linked immunosorbent spot assay response, highlighting the importance of including multiple antigen epitopes in the vaccine cocktail.